Bristol's Poker Game: Doubling Down On Research
This article was originally published in The Pink Sheet Daily
Executive Summary
Medarex acquisition has interesting strategic parallels with the earlier Amgen/Abgenix deal, and demonstrates once again Bristol's distinctive approach of doubling down on research rather than protecting itself through diversification toward slower growth businesses.
You may also be interested in...
Bristol-Myers Squibb Buys Medarex: Adds Eighth ‘Pearl' To String
Bristol sees Medarex acquisition as a way to expand its immunology and oncology pipeline in preparing for Plavix generics in 2012.
Bristol-Myers Squibb Buys Medarex: Adds Eighth ‘Pearl' To String
Bristol sees Medarex acquisition as a way to expand its immunology and oncology pipeline in preparing for Plavix generics in 2012.
KRAS Testing Gets On Label Of EGFr Products; Will Tests Get To Clinic Soon?
Amgen feels the sales impact from excluding KRAS-positive patients from Vectibix treatment has already occurred, but the firms plans to co-market a test kit shortly.